NASDAQ:AVBP | Free Cash Flow | ArriVent BioPharma, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$41.89M
2025-12-31-$30.66M
2025-03-31-$68.01M
2024-12-31-$16.15M
2024-03-31-$18.63M
2023-12-31-$14.91M
2023-03-31-$16.88M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$160.59M
2024-12-31-$70.21M
2023-12-31-$55.84M